This study was designed to compare the efficacy and safety of 4.5g iv MP administered in 12 weeks and 4 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
70
Shanghai Institute of Endocrine and Metabolic Diseases Department of Endocrine and Metabolic Diseases, Ruijin Hospital
Shanghai, Shanghai Municipality, China
RECRUITINGresponse rate
Time frame: 3 months
change of CAS, adverse effects and retreat
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.